Kiniksa posts first-quarter loss
Kiniksa Pharmaceuticals Ltd, the commercial-stage biopharmaceutical company that proposes to change its place of incorporation from Bermuda to Britain, has reported a net loss for the 2024 first quarter of $17.7 million.
That compares with a net loss of $12.3 million for the first quarter of 2023.
Total revenue for the quarter was $79.9 million, which compares with $48.3 million in the prior year’s quarter.
First quarter total revenue included $1 million in licence and collaboration revenue, compared with $5.7 million in the prior year quarter.
Total operating expenses were $96.4 million, up from $59.5 million for the same period in the prior year.
As of March 31, Kiniksa had $213.6 million of cash, cash equivalents, and short-term investments and no debt, the company said.
Kiniksa has cited Bermuda’s decision to introduce a corporate income tax as among its reasons for seeking the move.
It has proposed a scheme of arrangement under which the company would redomicile to Britain.
Under Bermuda law, a scheme of arrangement must be approved by a company’s shareholders, and also requires the approval of the Supreme Court.
Shareholders of the company are to vote on the matter at a virtual meeting scheduled for June 5.
Need to
Know
2. Please respect the use of this community forum and its users.
3. Any poster that insults, threatens or verbally abuses another member, uses defamatory language, or deliberately disrupts discussions will be banned.
4. Users who violate the Terms of Service or any commenting rules will be banned.
5. Please stay on topic. "Trolling" to incite emotional responses and disrupt conversations will be deleted.
6. To understand further what is and isn't allowed and the actions we may take, please read our Terms of Service
